Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

94.20CHF
18 Apr 2019
Change (% chg)

CHF-0.10 (-0.11%)
Prev Close
CHF94.30
Open
CHF94.00
Day's High
CHF94.40
Day's Low
CHF91.80
Volume
9,116
Avg. Vol
16,444
52-wk High
CHF150.00
52-wk Low
CHF76.10

Select another date:

Wed, Apr 10 2019

BRIEF-Cosmo Pharmaceuticals: Worldwide Distribution Agreement Of AI Device In Colonoscopy With Medtronic

* COSMO PHARMACEUTICALS ANNOUNCES REVOLUTIONARY ARTIFICIAL INTELLIGENCE DEVICE IN COLONOSCOPY TO DETECT LESIONS AND WORLDWIDE DISTRIBUTION AGREEMENT WITH MEDTRONIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Announces Submission Of Remimazolam NDA To FDA

* ANNOUNCES SUBMISSION OF REMIMAZOLAM NDA TO FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals FY Oper Loss Widens To EUR 16.6 Mln

* FY REVENUE EUR 65.6 MILLION COMPARED TO EUR 67.2 MILLION IN 2017

BRIEF-Cosmo Pharmaceuticals Announces Denial Of Methylene Blue MMX Appeal

* COSMO PHARMACEUTICALS ANNOUNCES DENIAL OF METHYLENE BLUE MMX APPEAL AND BEGINNING OF ACTIVITY TO START SECOND PHASE III TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

BRIEF-Cosmo Pharma Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets With EMA

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

BRIEF-Cosmo Pharmaceuticals: Regulatory Update For Methylene Blue MMX

* NOW IN PROCESS OF FILING A NEW APPEAL TO OFFICE OF NEW DRUGS (OND), CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Launches Offering Of Senior Unsecured Convertible Bonds Due 2023

* LAUNCH OF OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 2023

BRIEF-Cosmo Pharmaceuticals: FDA Grants Approval For Aemcolo (Tm) (Rifamycin)

* FDA GRANTS APPROVAL FOR AEMCOLO (TM) (RIFAMYCIN), THE FIRST APPROVED ANTIBIOTIC TO TREAT TRAVELER'S DIARRHEA FOR TEN YEARS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: